D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal Article
Evolution of combined modality therapy for stage III non-small-cell lung cancer.
TL;DR: The PV regimen produced a significantly shorter survival compared with the PGV combination; since this difference in survival complied with one of the early stopping rules, accrual in the PV arm was discontinued.
Journal ArticleDOI
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.
George Somlo,Joseph A. Sparano,Tessa Cigler,Gini F. Fleming,Thehang Luu,Arti Hurria,Joanne E. Mortimer,Paul Frankel,Helen K. Chew,Rita Nanda,Cynthia X. Ma,Alice P. Chen,Agustin A. Garcia,Linda T. Vahdat,David R. Gandara,Jeffrey N. Weitzel +15 more
TL;DR: A phase I trial of carboplatin (Carb) and velapirib [V], a PARP inhibitor, to define dose limiting toxicities [(DLT) during cycle (C) 1] and the maximum tolerated dose (MTD).
Journal ArticleDOI
O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment
Fred R. Hirsch,Jason McCoy,Frederico Cappuzzo,W. Howard Jack,Paul H. Gumerlock,L. Crinò,Wilbur A. Franklin,David R. Gandara,Marileila Varella-Garcia,Paul A. Bunn +9 more
Journal ArticleDOI
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: A California cancer consortium phase II study (NCI 7003)
Suresh S. Ramalingam,Angela M. Davies,Jeffrey Longmate,Martin J. Edelman,Primo N. Lara,Everett E. Vokes,Miguel A. Villalona-Calero,Barbara J. Gitlitz,Karen L. Reckamp,Ravi Salgia,John J. Wright,Chandra P. Belani,David R. Gandara +12 more
TL;DR: Bortezomib is tolerated well and is associated with modest anticancer activity in patients with advanced BAC, including patients who progressed on EGFR inhibitor therapy.
Journal ArticleDOI
83OA phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A
Vassiliki A. Papadimitrakopoulou,Mary W. Redman,Hossein Borghaei,Saiama N. Waqar,Francisco Robert,Gauri J. Kiefer,Shannon McDonough,Roy S. Herbst,Karen Kelly,David R. Gandara +9 more